An approach for the transition from systemic immunosuppressants to dupilumab

L. E.M. de Wijs; J. P. Thyssen; C. Vestergaard; H. B. Thio; A. C.M. Kunkeler; T. Biedermann; D. J. Hijnen

doi:10.1111/jdv.16941

An approach for the transition from systemic immunosuppressants to dupilumab

L. E.M. de Wijs, J. P. Thyssen, C. Vestergaard, H. B. Thio, A. C.M. Kunkeler, T. Biedermann, D. J. Hijnen^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › Professional › peer-review

2 Citations (Scopus)

10 Downloads (Pure)

Original language	English
Pages (from-to)	e221-e223
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	3
Early online date	13 Sep 2020
DOIs	https://doi.org/10.1111/jdv.16941
Publication status	Published - Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.16941Licence: CC BY

An approach for the transition from systemic immunosuppressants to dupilumabFinal published version, 367 KBLicence: CC BY

Cite this

@article{ad3c7054b5cd4279b83e2e348fffa63e,

title = "An approach for the transition from systemic immunosuppressants to dupilumab",

author = "{de Wijs}, {L. E.M.} and Thyssen, {J. P.} and C. Vestergaard and Thio, {H. B.} and Kunkeler, {A. C.M.} and T. Biedermann and Hijnen, {D. J.}",

note = "Funding Information: L.E.M. de Wijs, H.B. Thio and A.C.M. Kunkeler have none to declare. J.P. Thyssen attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, AbbVie and Sanofi Genzyme; received speaker honorarium from LEO Pharma, AbbVie, Regeneron and Sanofi Genzyme; and received research grants from Regeneron and Sanofi Genzyme. C. Vestergaard has acted as speaker and/or investigator for Sanofi Genzyme, AbbVie, LEO Pharma, Galapagos, Pierre Fabre Dermo‐Cosmetique and Novartis. D.J. Hijnen has been an investigator for AbbVie, LEO Pharma, Galderma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; and consultant for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen, Pfizer and Lilly. T. Biedermann has been an institution investigator for AbbVie, LEO Pharma, Novartis, Sanofi/Regeneron, Janssen, Pfizer and Lilly; consultant for Alk‐Abell{\'o}, Mylan, Novartis and Sanofi/Regeneron; and received honorarium for talks or research grant from Alk‐Abell{\'o}, Celgene, Mylan, Novartis, Phadia/Thermo Fisher and Sanofi/Regeneron. ",

year = "2021",

month = mar,

doi = "10.1111/jdv.16941",

language = "English",

volume = "35",

pages = "e221--e223",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - An approach for the transition from systemic immunosuppressants to dupilumab

AU - de Wijs, L. E.M.

AU - Thyssen, J. P.

AU - Vestergaard, C.

AU - Thio, H. B.

AU - Kunkeler, A. C.M.

AU - Biedermann, T.

AU - Hijnen, D. J.

N1 - Funding Information: L.E.M. de Wijs, H.B. Thio and A.C.M. Kunkeler have none to declare. J.P. Thyssen attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, AbbVie and Sanofi Genzyme; received speaker honorarium from LEO Pharma, AbbVie, Regeneron and Sanofi Genzyme; and received research grants from Regeneron and Sanofi Genzyme. C. Vestergaard has acted as speaker and/or investigator for Sanofi Genzyme, AbbVie, LEO Pharma, Galapagos, Pierre Fabre Dermo‐Cosmetique and Novartis. D.J. Hijnen has been an investigator for AbbVie, LEO Pharma, Galderma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; and consultant for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen, Pfizer and Lilly. T. Biedermann has been an institution investigator for AbbVie, LEO Pharma, Novartis, Sanofi/Regeneron, Janssen, Pfizer and Lilly; consultant for Alk‐Abelló, Mylan, Novartis and Sanofi/Regeneron; and received honorarium for talks or research grant from Alk‐Abelló, Celgene, Mylan, Novartis, Phadia/Thermo Fisher and Sanofi/Regeneron.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85092197865&partnerID=8YFLogxK

U2 - 10.1111/jdv.16941

DO - 10.1111/jdv.16941

M3 - Article

C2 - 32920932

AN - SCOPUS:85092197865

VL - 35

SP - e221-e223

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 3

ER -

An approach for the transition from systemic immunosuppressants to dupilumab

UN SDGs

Access to Document

Other files and links

Cite this